Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-5804
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlmstedt, Katrin-
dc.contributor.authorMendoza, S.-
dc.contributor.authorOtto, M.-
dc.contributor.authorBattista, M. J.-
dc.contributor.authorSteetskamp, Joscha-
dc.contributor.authorHeimes, Anne-Sophie-
dc.contributor.authorKrajnak, Slavomir-
dc.contributor.authorPoplawski, A.-
dc.contributor.authorGerhold-Ay, A.-
dc.contributor.authorHasenburg, Annette-
dc.contributor.authorDenkert, Carsten-
dc.contributor.authorSchmidt, Marcus-
dc.date.accessioned2021-05-11T09:06:47Z-
dc.date.available2021-05-11T09:06:47Z-
dc.date.issued2020-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/5813-
dc.description.abstractPURPOSE Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict® on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test. METHODS Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated between 2011 and 2016 were included in this study to investigate the role of EndoPredict® (EPclin) in the treatment of early breast cancer. A main study aim was to analyze the changes in therapy recommendations with and without EPclin. In addition, the impact of clinico-pathological parameters for the decision to perform EPclin was examined by Pearson's chi-squared test (χ2-test) and Fisher's exact test as well as univariate and multivariate logistic regressions. RESULTS In a cohort of 869 consecutive early HR-positive, HER-negative breast cancer patients, EPclin was utilized in 156 (18.0%) patients. EPclin led to changes in therapy recommendations in 33.3% (n = 52), with both therapy escalation in 19.2% (n = 30) and de-escalation in 14.1% (n = 22). The clinico-pathological factors influencing the use of EPclin were age (P < 0.001, odds ratio [OR] 0.498), tumor size (P = 0.011, OR 0.071), nodal status (P = 0.021, OR 1.674), histological grade (P = 0.043, OR 0.432), and Ki-67 (P < 0.001, OR 3.599). CONCLUSIONS EPclin led to a change in therapy recommendations in one third of the patients. Clinico-pathological parameters such as younger age, smaller tumor size, positive nodal status, intermediate histological grade and intermediate Ki-67 had a significant influence on the use of EndoPredict®.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleEndoPredict® in early hormone receptor-positive, HER2-negative breast canceren_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-5804-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleBreast cancer research and treatmentde
jgu.journal.volume182de
jgu.pages.start137de
jgu.pages.end146de
jgu.publisher.year2020-
jgu.publisher.nameSpringer Science + Business Media B.V.de
jgu.publisher.placeDordrechtde
jgu.publisher.urihttps://doi.org/10.1007/s10549-020-05688-1de
jgu.publisher.issn1573-7217de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1007/s10549-020-05688-1-
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
almstedt_k.-endopredict®_i-20210421200952037.pdf729.63 kBAdobe PDFView/Open